MARKET

TSHA

TSHA

Taysha Gene Therapies, Inc.
NASDAQ
3.720
-0.050
-1.33%
After Hours: 3.750 +0.03 +0.81% 19:40 11/20 EST
OPEN
3.670
PREV CLOSE
3.770
HIGH
3.795
LOW
3.600
VOLUME
3.15M
TURNOVER
--
52 WEEK HIGH
7.30
52 WEEK LOW
3.455
MARKET CAP
1.21B
P/E (TTM)
-8.8998
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Sticks to Its Buy Rating for Taysha Gene Therapies (TSHA)
TipRanks · 17h ago
Weekly Report: what happened at TSHA last week (1109-1113)?
Weekly Report · 4d ago
Taysha Earnings Call Highlights Gene Therapy Launch Readiness
TipRanks · 6d ago
BMO Capital Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
TipRanks · 11/13 16:55
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
TipRanks · 11/13 14:38
Taysha Gene Therapies (TSHA) Receives a Buy from Canaccord Genuity
TipRanks · 11/13 14:06
Taysha Q3 Loss Widens On Higher Expenses; REVEAL 6-Month Interim Data Due In H1'27
NASDAQ · 11/13 09:30
Taysha (TSHA) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/13 06:13
More
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.

Webull offers Taysha Gene Therapies Inc stock information, including NASDAQ: TSHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TSHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TSHA stock methods without spending real money on the virtual paper trading platform.